跳至主要内容
临床试验/ACTRN12609000241235
ACTRN12609000241235尚未招募3 期

A Trial Assessing omega-3 fatty acids (N-3) as Treatment for Injury-induced Cachexia

Dr Michelle Miller0 个研究点目标入组 150 人开始时间: 2009年5月11日最近更新:
适应症

试验速览

阶段
3 期
状态
尚未招募
入组人数
150

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
65 Years 至 o limit(—)
性别
All

入选标准

  • Aged >65 years
  • - PFF confirmed by radiology report
  • - Undergone surgery for fixation of hip fracture
  • - Reside within existing local service boundaries
  • - Community dwelling
  • - Preliminary evidence of cachexia (CRP =6mg/L)
  • - At risk of significant weight loss (SNAQ score =14/20)

排除标准

  • - Severe cognitive impairment (MMSE <18/30)
  • - PFF not fall-related, is pathological or is peri-prosthetic
  • - Initiation of anti-inflammatory drugs or corticosteroids within the previous two weeks
  • - Ingestion of =2g total omega-3 daily as per fish FFQ
  • - Seafood allergy
  • - Life expectancy <12 weeks
  • - Inability to communicate effectively due to blindness, deafness or lack of a translator
  • - Inability to provide informed consent
  • - Diagnosed with one of the following haemorrhagic stroke risk factors (Unstable hypertension, Atrial fibrillation, Inherited disorders such as polycystic kidney disease, Ehlers-Danlos syndrome type IV, neurofibromatosis type I, Marfan syndrome, moyamoya disease)
  • - Diagnosed with a bleeding disorders such as the following (von Willebrand disease or Haemophilia
  • - Receiving treatment doses of any antithrombotic agent
  • - Those on dual anti-platelet function drugs or any anti-platelet drugs with exception to low dose aspirin.

研究者

相似试验